Pub. Date : 2020 Feb
PMID : 31901955
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Furthermore, CUDC-907 is an oral inhibitor of class I phosphoinositide 3-kinase (PI3K) as well as class I and II histone deacetylase (HDAC) enzymes. | CUDC-907 | histone deacetylase 9 | Homo sapiens |
| 2 | Furthermore, CUDC-907 is an oral inhibitor of class I phosphoinositide 3-kinase (PI3K) as well as class I and II histone deacetylase (HDAC) enzymes. | CUDC-907 | histone deacetylase 9 | Homo sapiens |
| 3 | METHODS: In this study, we evaluated the effect of combination therapy of CUDC-907 and ABL TKIs, using BCR-ABL-positive cell lines and primary samples. | CUDC-907 | ABL proto-oncogene 1, non-receptor tyrosine kinase | Homo sapiens |
| 4 | CONCLUSION: Taken together, our results indicate that administration of CUDC-907, a dual PI3K and HDAC inhibitor, may be an effective strategy against ABL TKI-resistant cells, including cells harboring the T315I mutation. | CUDC-907 | histone deacetylase 9 | Homo sapiens |
| 5 | CONCLUSION: Taken together, our results indicate that administration of CUDC-907, a dual PI3K and HDAC inhibitor, may be an effective strategy against ABL TKI-resistant cells, including cells harboring the T315I mutation. | CUDC-907 | ABL proto-oncogene 1, non-receptor tyrosine kinase | Homo sapiens |
| 6 | Moreover, CUDC-907 may enhance the cytotoxic effects of ABL TKI when a combined treatment strategy is used against Philadelphia chromosome-positive leukemia cells. | CUDC-907 | ABL proto-oncogene 1, non-receptor tyrosine kinase | Homo sapiens |